Delcath Systems, Inc. (DCTH): Price and Financial Metrics


Delcath Systems, Inc. (DCTH)

Today's Latest Price: $16.89 USD

0.20 (1.20%)

Updated Jan 25 6:55pm

Add DCTH to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 188 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

DCTH Stock Price Chart Interactive Chart >

Price chart for DCTH

DCTH Price/Volume Stats

Current price $16.89 52-week high $19.82
Prev. close $16.69 52-week low $5.15
Day low $16.31 Volume 70,100
Day high $16.98 Avg. volume 99,640
50-day MA $16.05 Dividend yield N/A
200-day MA $11.70 Market Cap 69.54M

Delcath Systems, Inc. (DCTH) Company Bio


Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.


DCTH Latest News Stream


Event/Time News Detail
Loading, please wait...

DCTH Latest Social Stream


Loading social stream, please wait...

View Full DCTH Social Stream

Latest DCTH News From Around the Web

Below are the latest news stories about Delcath Systems Inc that investors may wish to consider to help them evaluate DCTH as an investment opportunity.

Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. The presentation is now available “on-demand” by visiting https://hcwevents.com/bioconnect/About Delcath Systems, Inc.Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not...

Yahoo | January 11, 2021

Delcath Systems Announces Completion of Underwritten Public Offering

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the completion of an underwritten public offering of 1,679,031 shares of its common stock, including 219,004 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares of common stock. All of the shares were offered by Delcath at a price to the public of $13.25 per share. The Company now estimates that the gross proceeds of the offering to the Company are expected to be approximately $22.2 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. Delcath intends to ...

Yahoo | December 11, 2020

Delcath Systems Announces Pricing of Public Offering of Common Stock - Stocks News Feed

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the pricing of an underwritten public offering of 1,460,027 shares of its common stock at a public offering price of $13.25 per share.… Read More »Delcath Systems Announces Pricing of Public Offering of Common Stock

Stocks News Feed | December 9, 2020

Kevin Muir Joins Delcath Systems, Inc. as VP, Commercial Operations

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced Kevin Muir has joined the company as Vice President of Commercial Operations. In his most recent role, Mr. Muir was Director of Sales for the Embolics Interventional Oncology business unit of BTG plc where he played a key role in growing that business from $40 million to $180 million at which time BTG was acquired by Boston Scientific. Gerard Michel, CEO of Delcath, commented, “We are thrilled that Kevin is joining the Delcath team as VP of Commercial Operations. He is a seasoned and accomplished leader with experience across multiple innovative medical technologies with a recent foc...

Yahoo | December 7, 2020

Delcath Systems, Inc. Announces Third Quarter 2020 Results

Conference Call Today at 8:30am Eastern TimeNEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2020. Recent Business HighlightsDuring and since the third quarter of 2020, the company: * Strengthened the executive team with the appointment of Gerard Michel as Chief Executive Officer. * Announced the conditional acceptance by the FDA of the trade name HEPZATO™ KIT (melphalan hydrochloride for injection/hepatic delivery system) for Melphalan/HDS. * Announced the treatment of the final patient in the FOCUS trial; to date, 91 patients have been treated w...

Yahoo | November 11, 2020

Read More 'DCTH' Stories Here

DCTH Price Returns

1-mo N/A
3-mo 58.29%
6-mo 34.69%
1-year N/A
3-year -99.87%
5-year -100.00%
YTD -5.75%
2020 -15.67%
2019 -89.16%
2018 -99.39%
2017 -99.97%
2016 -88.50%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8439 seconds.